|Enter Our Monthly Contest!
Each month, a single Customized Technology Services
(CTS) test will be given away at random.
FOR IMMEDIATE RELEASE
W. Richard Ulmer
INVITRO INTERNATIONAL REPORTS
SECOND QUARTER RESULTS AND COMMENTS ON ANNUAL MEETING
Company Looks Forward with Cautious Optimism
Irvine, CA, May 5, 1998 -- InVitro International's (Bulletin Board
Symbol "INVI") second fiscal quarter, ended March 31, 1998, resulted
with revenues of $135,744, an increase of 2% over the revenues of
$133,272 for quarter ended December 31, 1997; net loss for the second
quarter was $36,069 or .003¢ per share, a decrease of $ 21,700 compared
to first quarter losses and 91% less than second quarter 1997 losses
of $395,000, or .02¢ per share. Management anticipates that the
losses will continue to narrow if revenues increase only slightly
above their current rate.
President and Chief Executive Officer, W. Richard Ulmer, stated
"INVI's unaudited second quarter financial for the period ending
March 31, 1998, again showed an increase in cash with slightly higher
sales than in the first quarter(ended December 31, 1997); profit
and loss results were very near break-even for this second quarter."
Most of the quarter’s loss is attributable to fiscal year end audit,
and shareholder/ broker printing and mailing expenses.
In reviewing current opportunities for INVI, Ulmer indicated that
the recent increase in Department of Transportation enforcement
personnel appears to have spurred more interest in Corrositex® testing
in the United States; in addition, INVI’s agents and partner laboratories
in both Asia and Europe have developed several new business opportunities
for the Company’s Irritection Assay System® during the last year.
Ulmer commented, "InVitro International has demonstrated a mental
toughness and shown its ability to stay on course under difficult
circumstances; we continue to believe that we are ahead of our time
both with the non-animal testing core business as well as with the
infant safety and identification product, Guardian DNA." He continued
by saying, "with the November 1997 United Kingdom legislation preventing
future new finished cosmetics from being tested on animals, there
is potential for more demand for non-animal test methodologies such
as INVI’s Irritection Assay System in its Ocular and Dermal forms."
Finally, Ulmer noted that as had been mentioned in the recent
1997 Letter to Shareholder, the Company’s current plan of operation
includes a continuing effort to find a suitable merger partner.
There is no new news on that activity at this time.
InVitro’s annual shareholder’ meeting was held on April 17, 1998,
at which five incumbent directors were re-elected.
InVitro International is engaged in the development, manufacture
and sale of proprietary, non-animal toxicity testing products and
services that ensure the safekeeping of humans and the environment,
and that minimize animal testing in commercial and academic enterprise.
Certain information in this document includes "forward-looking
statements" within the meaning of applicable securities laws. In
addition, from time to time the Company or its executive officers
have made or may make forward-looking statements, orally or in writing,
that involve substantial risks and uncertainties. Actual results
could differ materially from those projected or suggested by any
forward-looking statements as a result of a wide variety of factors
and conditions, including but not limited to, the ability of the
Company to continue as a going concern, market acceptance of new
products and technologies, economic, competitive, governmental and
technological factors affecting the Company’s operations, markets,
services and prices, significant disruptions caused by third parties
failures to address the Year 2000 issues, litigation costs, changes
in the Company’s operations, unanticipated events and various other
factors. The reader is specifically referred to disclosures contained
in this document and in prior documents publicly disseminated by
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
Three months ended March 31 Six months ended March 31
1998 1997 1998 1997
Revenues $136,000 $164,000 $269,000 $423,000
Costs and expenses 172,000 567,000 363,000 1,346,000
Loss from operations (36,000) (403,000) (94,000) (923,000)
Other income 0 8,000 0 22,000
Net loss $(36,000) $(395,000) $(94,000) $(901,000)
Loss per common share $(0.003) (0.02) $(0.01) (0.06)
Weighted average common
shares outstanding 14,028,300 14,023,300
Condensed Consolidated Balance Sheet
March 31, March 31,
Cash and cash equivalents $56,000 54,000
Other current assets 566,000 584,000
Total current assets 622,000 638,000
Noncurrent assets 204,000 255,000
Total assets $826,000 $893,000
Current liabilities $199,000 $169,000
Shareholders' equity 627,000 724,000
Total liabilities & equity $826,000 893,000
17751 Sky Park East, Suite G
Irvine, CA 92614
949-851-8356 (International callers)
949- 851-4985 Fax